Literature DB >> 28356965

Overexpression of KAI1 inhibits retinoblastoma metastasis in vitro.

Hui Yan1, Xunda Ji1, Jing Li1, Lei Zhang2, Peiquan Zhao1.   

Abstract

The present study aimed to investigate the expression of cluster of differentiation 82 (KAI1), a gene involved in the suppression of tumor metastasis, in human retinoblastoma (RB) tissue and to study the effect of KAI1 expression on RB cell migration and invasion. KAI1 expression was examined in 26 patients with non-invasive and invasive retinoblastoma using reverse transcription-quantitative polymerase chain reaction and western blot analysis. A lentiviral vector containing KAI1 cDNA was used to transfect the two RB cell lines, HXO-Rb44-Gl and Y79. Following successful transfection, the migratory and invasive capacity of the two RB cell lines was evaluated using a Transwell® migration assay. KAI1 expression was observed to be downregulated in invasive RB compared to non-invasive RB. The migratory and invasive capacities of KAI1 transfected cell lines were significantly decreased compared to those of the control cells. KAI1 may be involved in retinoblastoma metastasis, and increased expression of KAI1 significantly inhibits the metastatic ability of RB cells in vitro.

Entities:  

Keywords:  cluster of differentiation 82; invasion; metastasis; migration; retinoblastoma

Year:  2016        PMID: 28356965      PMCID: PMC5351286          DOI: 10.3892/ol.2016.5507

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 3.  Basic understanding of current classification and management of retinoblastoma.

Authors:  Carol L Shields; Jerry A Shields
Journal:  Curr Opin Ophthalmol       Date:  2006-06       Impact factor: 3.761

4.  Clinical presentation and survival of retinoblastoma in Indian children.

Authors:  Bhavna Chawla; Fahmi Hasan; Rajvardhan Azad; Rachna Seth; Ashish Datt Upadhyay; Sushmita Pathy; R M Pandey
Journal:  Br J Ophthalmol       Date:  2015-06-10       Impact factor: 4.638

5.  Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.

Authors:  Andreas M Stark; Kerrin Tongers; Nicolai Maass; H Maximilian Mehdorn; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-08       Impact factor: 4.553

6.  Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.

Authors:  Ira J Dunkel; Yasmin Khakoo; Nancy A Kernan; Timothy Gershon; Stephen Gilheeney; David C Lyden; Suzanne L Wolden; Manuela Orjuela; Sharon L Gardner; David H Abramson
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

7.  KAI1 inhibits HGF-induced invasion of pancreatic cancer by sphingosine kinase activity.

Authors:  Xu Liu; Xiao-Zhong Guo; Wei-Wei Zhang; Zhuo-Zhuang Lu; Qun-Wei Zhang; Hai-Feng Duan; Li-Sheng Wang
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2011-04

8.  [Expression changes of tumor metastasis-related genes after overexpression of KAI1 in retinoblastoma Y79 cells].

Authors:  Xun-da Ji; Hui Yan; Pei-quan Zhao
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2012-12

9.  KAI1 gene suppresses invasion and metastasis of hepatocellular carcinoma MHCC97-H cells in vitro and in animal models.

Authors:  Jian-Min Yang; Zhi-Hong Peng; Sui-Hai Si; Wei-Wen Liu; Yuan-Hui Luo; Zai-Yuan Ye
Journal:  Liver Int       Date:  2007-11-19       Impact factor: 5.828

10.  KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.

Authors:  Jung-Jin Park; Yeung Bae Jin; Yoon-Jin Lee; Jae-Seon Lee; Yun-Sil Lee; Young-Gyu Ko; Minyoung Lee
Journal:  BMC Cancer       Date:  2012-03-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.